Refurbishing Ventilators: A New 501(c)3 Begins Returning Tired Ventilators To Service COVID-19 Patients

The Co-Vents team of ventilator and pulmonary experts have received expedited approval from the IRS for their 501(c)3 not-for-profit designation in just 11 days after company formation.

This designation allows Co-Vents donors to receive a tax deduction for supporting our mission of returning retired ventilators to active service for COVID-19 patients. Those interested in joining this life-saving mission can donate directly here.

Co-Vents will draw upon its founders’ long history in the manufacturing of leading-edge respiratory ventilators to refurbish “retired” ventilators and quickly bring them to market to address the pandemic of respiratory illness brought on by the coronavirus. For patients whose breathing has been significantly compromised by the virus, ventilators deliver air to the lungs to help keep these patients alive.  Our average turnaround time from ventilator donation to live clinical use will be just over a week.

“Our team is energized by the donation response that we have received to our life-saving mission,” Paul Woodring, CEO and Co-Founder of Co-Vents, said. “We are focused on closing this short-term 60-day ventilator supply gap for COVID-19 patients while new ventilator production ramps up.”

The first donated and acquired ventilators have been delivered to our designated FDA and ISO approved refurbishment facilities.  Once the FDA certification is completed, Co-Vents will work with the state and federal response teams to ensure that our ventilators are delivered to patients in the areas hardest hit by the Coronavirus.

“We are grateful to our attorneys from Charitable Allies and the IRS for working together to approve our expedited 501(c)3 request in record time.  This designation allows donors to receive a tax deduction while funding this critical mission,” Co-Founder Michael Raymer said.

SourceCo-Vents

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”